Expert Interview
A Second Look: Exploring the recent FDA approval of DAWNZERA (donidalorsen) from Ionis Pharmaceuticals and ANDEMBRY® (garadacimab-gxii) from CSL for patients with hereditary angioedema
Ticker(s): IONS, CSLLYInstitution: Hurley Medical Center
- Allergist/Immunologist at Hurley Medical Center
- Manages 30+ HAE patients monthly and 100 patients with AD
- Familiar with clinical data investigational therapeutics for HAE
What are your thoughts on DAWNZERA’s mechanism of action, which reduces the production of plasma prekallikrein?
Added By:What are your thoughts on ANDEMBRY's mechanism of action, which targets factor XIIa?
Added By:What impact do you think DAWNZERA and ANDEMBRY will have on the treatment space for hereditary angioedema?
Added By:Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
